Vogt-Koyanagi-Harada disease (VKHD) is a multisystemic disorder characterized by granulomatous panuveitis variably combined with T cell-mediated neurologic and cutaneous manifestations. Early and aggressive treatment with systemic corticosteroids is the mainstay of treatment for VKHD. Additional use of immunosuppressants, intravenous immunoglobulins, and tumor necrosis factor-alpha inhibitors can help the most severely affected patients and work as corticosteroid-sparing agents. We report the case of a young woman with relapsing and multiresistant VKHD who demonstrated a stable remission of both uveitis and high-frequency hearing loss following rituximab intravenous administration (1 g. twice, 2 weeks apart, and 6 months later).
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease|
|Citazione:||Caso, F., Rigante, D., Vitale, A., Costa, L., Bascherini, V., Latronico, E., et al. (2015). Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. CLINICAL RHEUMATOLOGY, 34(10), 1817-1820.|
|Appare nelle tipologie:||1.1 Articolo in rivista|